A Phase 2 interventional study of MGL-3196 and Placebo in Non-alcoholic Steatohepatitis, sponsored by Madrigal Pharmaceuticals, Inc.. Completed at 26 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-23.
Sponsored by Madrigal Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 127th largest by enrollment of the 460 interventional ones that give a count, is one of 28 that started in 2016, is one of 192 in phase 2, and was the 188th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
Regeneron Pharmaceuticals · Sites in United States, Puerto Rico, United Kingdom
Ages 18–75
Columbia University · Sites in United States
Ages 18–65
Regeneron Pharmaceuticals · Sites in United States
Ages 18–75
GlaxoSmithKline · Sites in United States
Ages 18–70
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
547 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 93 · Phase 2 213 · Phase 3 36 · Phase 4 13
First in 2000; this study’s year is marked. 28 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 125 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 56 across the 460 interventional studies, 90 across the 85 observational. Of the 420 that completed or were terminated, 216 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
246 of 547 have an industry lead sponsor. The 10 most frequent:
Madrigal Pharmaceuticals, Inc. is the lead sponsor of 21 studies on the registry; 5 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Madrigal Pharmaceuticals, Inc. has 5 studies filed under Non-alcoholic Fatty Liver Disease — fewer than ten, so there is no comparison to draw.
22 of the studies in Non-alcoholic Fatty Liver Disease with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04951219Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE) | 2027-03 |
| NCT04833140Phase 3Massachusetts General HospitalEstrogen Administration for the Treatment of NASH in Postmenopausal Women | 2027-07-09 |
| NCT00983463Vanderbilt UniversityAbundance and Distribution of Lipids and Proteins in Nonalcoholic Fatty Liver Disease (NAFLD) | 2026-11 |
| NCT05165706Stanford UniversityLongitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance | 2026-11-30 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
Add all 22 to your calendar (.ics) → With an account.
Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 on the percent change in hepatic fat fraction from baseline in participants with biopsy-proven Non-alcoholic Steatohepatitis (NASH).
Inclusion Criteria. Participants who meet all of the following criteria will be eligible to participate in the study:
-proven NASH. Must have had prior liver biopsy within 180 days of randomization with fibrosis stage 1 to 3 and a non-alcoholic fatty liver disease activity score (NAS) of ≥4 with a score of 1 or more in each of the following NAS components:
Exclusion Criteria. Participants who meet any of the following criteria will be excluded from participation in the study:
Note: Unless otherwise specified, repeat testing may be performed in consultation with the Medical Monitor.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Study Drug
Drug: MGL-3196
Matching Placebo
Drug: Placebo
Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF)
The primary endpoint was relative change in MRI-PDFF assessed hepatic fat fraction compared with placebo at Week 12 in participants who had both a baseline and Week 12 MRI-PDFF. Least squares (LS) mean was provided for the statistical comparison of MGL-3196 versus placebo.
Time frame: Week 12
Percentage Of Participants With Adverse Events (AEs)
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
Time frame: Week 12 and Week 36
Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF
The endpoint was relative change assessed hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the statistical comparison of MGL-3196 versus placebo.
Time frame: Week 36
Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF
The endpoint was change in MRI-PDFF assessed absolute hepatic fat fraction compared with placebo at Week 12. LS mean was provided for the comparison of MGL-3196 versus placebo.
Time frame: Week 12
Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF
The endpoint was change in assessed absolute hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the comparison of MGL-3196 versus placebo.
Time frame: Week 36
Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 12
The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 12.
Time frame: Week 12
Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 36
The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 36.
Time frame: Week 36
Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36
The NAS is a histologic scale for non-alcoholic steatohepatitis (NASH) activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 1-point or greater reduction in NAS.
Time frame: Week 36
Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS.
Time frame: Week 36
Percentage Of Participants Achieving A 2-Point Reduction In NAS And Either A ≥1-Point Reduction In Lobular Inflammation Or Hepatocellular Ballooning At Week 36
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS and a 1-point or greater reduction in lobular inflammation or hepatocellular ballooning.
Time frame: Week 36
Percentage Of Participants Achieving A 2-Point Reduction In NAS Without Fibrosis Worsening At Week 36
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). Fibrosis stage (0 to 3) was also included in the assessment. The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS without worsening fibrosis.
Time frame: Week 36
Percentage Of Participants With A Reduction In Hepatocellular Steatosis At Week 36
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular steatosis.
Time frame: Week 36
Percentage Of Participants With A Reduction In Lobular Inflammation At Week 36
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in lobular inflammation.
Time frame: Week 36
Percentage Of Participants With A Reduction In Hepatocellular Ballooning At Week 36
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular ballooning.
Time frame: Week 36
Percentage Of Participants Achieving NASH Resolution With At Least 2-Point Reduction In NAS At Week 36
The endpoint presented the percentage of participants achieving NASH resolution with a 2-point reduction at Week 36.
Time frame: Week 36
Percent Change From Baseline To Week 12 In High-sensitivity C-reactive Protein (hsCRP)
hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.
Time frame: Week 12
Percent Change From Baseline To Week 36 In hsCRP
hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.
Time frame: Week 36
Change From Baseline To Week 12 In Serum Alanine Aminotransferase (ALT)
Blood samples were collected to determine the effect of MGL-3196 on serum ALT.
Time frame: Week 12
Change From Baseline To Week 36 In ALT
Blood samples were collected to determine the effect of MGL-3196 on serum ALT.
Time frame: Week 36
Change From Baseline To Week 12 In Serum Aspartate Aminotransferase (AST)
Blood samples were collected to determine the effect of MGL-3196 on serum AST.
Time frame: Week 12
Change From Baseline To Week 36 In AST
Blood samples were collected to determine the effect of MGL-3196 on serum AST.
Time frame: Week 36
Percent Change From Baseline To Week 12 In Lipid Parameters
Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein B (ApoB), and Apolipoprotein CIII (ApoCIII).
Time frame: Week 12
Percent Change From Baseline To Week 36 In Lipid Parameters
Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including LDL-C, HDL-C, non-HDL-C, TC, TG, ApoB, and ApoCIII.
Time frame: Week 36
Percent Change From Baseline To Week 12 In Lipid Parameter Lipoprotein(a) (Lp[a])
Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).
Time frame: Week 12
Percent Change From Baseline To Week 36 In Lipid Parameter Lp[a]
Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).
Time frame: Week 36
Change From Baseline To Week 12 And Week 36 In Cytokeratin-18 (CK-18)
Serum CK-18 fragments, detected using the M30 antibody, is a non-invasive biomarker for NASH that may reflect hepatocyte apoptosis.
Time frame: Week 12 and Week 36
Change From Baseline To Week 12 And Week 36 In Enhanced Liver Fibrosis (ELF) Test
The ELF Test is a non-invasive blood test that provides a simple, unitless numeric score that is used as a marker of collagen formation and fibrogenic activity and can be used to assess the risk of progression to cirrhosis. Scores below 9.8 indicate low risk of disease progression, and scores above 11.29 indicate high risk. The ELF score is derived from values of three serum biomarkers: hyaluronic acid (HA), procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1). The formula is 2.278 + 0.851 × ln(HA) + 0.751 × ln(PIIINP) + 0.394 × ln(TIMP-1); there are no minimum or maximum values.
Time frame: Week 12 and Week 36
Change From Baseline To Week 12 And Week 36 In Fibrosis-4 (Fib-4) Score
The Fib-4 score is a scoring system used to estimate the amount of scarring in the liver. It is based on common clinical parameters (age, AST, ALT, and platelets) and has been shown to have the best diagnostic accuracy for advanced fibrosis when compared with other noninvasive clinical scores. Scores are categorized into low (\<1.30), indeterminate (1.30-2.67), or high (\>2.67) risk of fibrosis. The formula for Fib-4 is: (Age \[yr\] x AST \[U/L\]) / ((PLT \[109/L\]) x (ALT \[U/L\])½); there are no minimum or maximum values
Time frame: Week 12 and Week 36
Change From Baseline of Thyrotropin at Week 12
Thyrotropin (TSH) was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Total Thyroxine at Week 12
Total thyroxine (FT4) was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Free Thyroxine at Week 12
Free thyroxine (FT4) was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Total Triiodothyronine at Week 12
Total Triiodothyronine (T3) was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Free Triiodothyronine at Week 12
Free triiodothyronine (T3) was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Thyroxine Binding Globulin at Week 12
Thyroxine Binding Globulin was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Reverse Triiodothyronine Globulin at Week 12
Reverse Triiodothyronine (T3) was assessed at each study visit.
Time frame: Baseline up to Week 12
Change From Baseline of Thyrotropin at Week 36
Tyrotropin (TSH) was assessed at each study visit.
Time frame: Baseline up to Week 36
Change From Baseline of Total Thyroxine at Week 36
Total thyroxine (FT4), thyrotropin (TSH) was assessed at each study visit.
Time frame: Baseline up to Week 36
Change From Baseline of Free Thyroxine Week 36
Total free thyroxine (FT4) was assessed at each study visit.
Time frame: Baseline up to Week 36
Change From Baseline of Total Triiodothyronine at Week 36
Total triiodothyronine (T3) was assessed at each study visit.
Time frame: Baseline up to Week 36
Change From Baseline of Free Triiodothyronine at Week 36
Free triiodothyronine (T3) was assessed at each study visit.
Time frame: Baseline up to Week 36
Change From Baseline of Thyroxine-Binding Globulin at Week 36
Thyroxine-binding globulin (TBG) was assessed at each study visit.
Time frame: Baseline up to Week 36
Change From Baseline of Reverse Triiodothyronine at Week 36
Reverse triiodothyronine (T3) was assessed at each study visit.
Time frame: Baseline up to Week 36
Participants underwent screening procedures within 42 days of randomization. To participate in the study, participants were required to have had a qualifying liver biopsy within 180 days of randomization.
| Milestone | MGL-3196 | Placebo |
|---|---|---|
| Started | 84 | 41 |
| Received at least 1 dose of study drug | 84 | 41 |
| Completed | 74 | 34 |
| Not completed | 10 | 7 |
| Withdrew: Lost to follow-up | 5 | 4 |
| Withdrew: Withdrawal by subject | 2 | 2 |
| Withdrew: Adverse event | 3 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Milestone | MGL-3196 | Placebo |
|---|---|---|
| Started | 17 | 14 |
| Completed | 16 | 13 |
| Not completed | 1 | 1 |
| Withdrew: Withdrawal by subject | 1 | 1 |
The primary endpoint was relative change in MRI-PDFF assessed hepatic fat fraction compared with placebo at Week 12 in participants who had both a baseline and Week 12 MRI-PDFF. Least squares (LS) mean was provided for the statistical comparison of MGL-3196 versus placebo.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Percent Change From Baseline To Week 12 In Hepatic Fat Fraction Assessed By Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) | -32.9 ± 3.0 | -10.4 ± 4.3 |
An AE was defined as any untoward medical occurrence in a clinical investigation participant administered a pharmaceutical product, which does not necessarily have a causal relationship with the treatment. A summary of serious and all other non-serious AEs, regardless of causality, is located in the Reported Adverse Events module.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Week 12 | 71.4 | 46.3 |
| Week 36 | 86.9 | 68.3 |
The endpoint was relative change assessed hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the statistical comparison of MGL-3196 versus placebo.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Percent Change From Baseline To Week 36 In Hepatic Fat Fraction Assessed By MRI-PDFF | -37.3 ± 3.7 | -8.9 ± 5.4 |
The endpoint was change in MRI-PDFF assessed absolute hepatic fat fraction compared with placebo at Week 12. LS mean was provided for the comparison of MGL-3196 versus placebo.
| percentage | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline To Week 12 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF | -7.0 ± 0.6 | -2.7 ± 0.8 |
The endpoint was change in assessed absolute hepatic fat fraction compared with placebo at Week 36. LS mean was provided for the comparison of MGL-3196 versus placebo.
| percentage | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline To Week 36 In Absolute Hepatic Fat Fraction Assessed By MRI-PDFF | -8.2 ± 0.7 | -2.9 ± 1.0 |
The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 12.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants With At Least 30% Relative Fat Reduction at Week 12 | 60.3 | 18.4 |
The endpoint presented the percentage of participants achieving a relative fat reduction of ≥30% at Week 36.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants With At Least 30% Relative Fat Reduction At Week 36 | 67.6 | 29.4 |
The NAS is a histologic scale for non-alcoholic steatohepatitis (NASH) activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 1-point or greater reduction in NAS.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants Achieving A 1-Point Reduction In Non-alcoholic Fatty Liver Disease Activity Score (NAS) At Week 36 | 76.7 | 64.7 |
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants Achieving A 2-Point Reduction In NAS At Week 36 | 56.2 | 32.4 |
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS and a 1-point or greater reduction in lobular inflammation or hepatocellular ballooning.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants Achieving A 2-Point Reduction In NAS And Either A ≥1-Point Reduction In Lobular Inflammation Or Hepatocellular Ballooning At Week 36 | 50.7 | 32.4 |
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). Fibrosis stage (0 to 3) was also included in the assessment. The endpoint presented the percentage of participants with a 2-point or greater reduction in NAS without worsening fibrosis.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants Achieving A 2-Point Reduction In NAS Without Fibrosis Worsening At Week 36 | 45.2 | 32.4 |
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular steatosis.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants With A Reduction In Hepatocellular Steatosis At Week 36 | 61.6 | 44.1 |
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in lobular inflammation.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants With A Reduction In Lobular Inflammation At Week 36 | 21.9 | 17.6 |
The NAS is a histologic scale for NASH activity, which combines into a single score steatosis (Grade 0 to 3), ballooning (Grade 0 to 2), and lobular inflammation (Grade 0 to 3). The endpoint presented the percentage of participants with a reduction in hepatocellular ballooning.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants With A Reduction In Hepatocellular Ballooning At Week 36 | 58.9 | 58.8 |
The endpoint presented the percentage of participants achieving NASH resolution with a 2-point reduction at Week 36.
| percentage of participants | MGL-3196 | Placebo |
|---|---|---|
| Percentage Of Participants Achieving NASH Resolution With At Least 2-Point Reduction In NAS At Week 36 | 27.4 | 14.7 |
hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Percent Change From Baseline To Week 12 In High-sensitivity C-reactive Protein (hsCRP) | 29.3 ± 18.36 | 13.2 ± 25.97 |
hsCRP was used as a non-invasive inflammation marker for this study. Blood samples were collected to determine the effect of MGL-3196 on hsCRP.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Percent Change From Baseline To Week 36 In hsCRP | 90.9 ± 67.52 | 34.0 ± 96.88 |
Blood samples were collected to determine the effect of MGL-3196 on serum ALT.
| IU/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline To Week 12 In Serum Alanine Aminotransferase (ALT) | -8.2 ± 2.7 | -5.2 ± 3.9 |
Blood samples were collected to determine the effect of MGL-3196 on serum ALT.
| IU/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline To Week 36 In ALT | -15.4 ± 4.7 | 11.0 ± 6.8 |
Blood samples were collected to determine the effect of MGL-3196 on serum AST.
| IU/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline To Week 12 In Serum Aspartate Aminotransferase (AST) | -5.8 ± 1.8 | -1.1 ± 2.5 |
Blood samples were collected to determine the effect of MGL-3196 on serum AST.
| IU/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline To Week 36 In AST | -7.4 ± 1.9 | 3.6 ± 2.8 |
Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), non-HDL-C, total cholesterol (TC), triglycerides (TG), apolipoprotein B (ApoB), and Apolipoprotein CIII (ApoCIII).
| percent change | MGL-3196 | Placebo |
|---|---|---|
| LDL-C | -10.6 ± 1.96 | 2.2 ± 2.79 |
| HDL-C | 5.0 ± 1.91 | 1.8 ± 2.72 |
| non-HDL-C | -12.1 ± 1.74 | 1.2 ± 2.47 |
| TC | -8.7 ± 1.37 | 0.9 ± 1.95 |
| TG | -6.8 ± 4.23 | 9.8 ± 6.01 |
| ApoB | -14.5 ± 1.59 | 0.8 ± 2.25 |
| ApoCIII | -9.1 ± 3.23 | 8.7 ± 4.62 |
| Lp(a) | -8.6 ± 7.54 | 12.3 ± 10.67 |
Blood samples were collected to determine the effect of MGL-3196 on lipid parameters including LDL-C, HDL-C, non-HDL-C, TC, TG, ApoB, and ApoCIII.
| percent change | MGL-3196 | Placebo |
|---|---|---|
| LDL-C | -11.0 ± 2.14 | 1.5 ± 3.11 |
| HDL-C | 10.5 ± 3.72 | 12.0 ± 5.41 |
| non-HDL-C | -14.0 ± 1.90 | 2.1 ± 2.76 |
| TC | -8.9 ± 1.61 | 3.6 ± 2.34 |
| TG | -19.8 ± 4.29 | 17.5 ± 6.24 |
| ApoB | -16.5 ± 1.79 | 0.9 ± 2.58 |
| ApoCIII | -12.0 ± 3.72 | 24.5 ± 5.42 |
| Lp(a) | 19.0 ± 10.95 | 39.0 ± 15.82 |
Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Percent Change From Baseline To Week 12 In Lipid Parameter Lipoprotein(a) (Lp[a]) | -8.6 ± 7.54 | 12.3 ± 10.67 |
Blood samples were collected to determine the effect of MGL-3196 on lipid parameter Lp(a).
| percent change | MGL-3196 | Placebo |
|---|---|---|
| Percent Change From Baseline To Week 36 In Lipid Parameter Lp[a] | 19.0 ± 10.95 | 39.0 ± 15.82 |
Serum CK-18 fragments, detected using the M30 antibody, is a non-invasive biomarker for NASH that may reflect hepatocyte apoptosis.
| U/L | MGL-3196 | Placebo |
|---|---|---|
| Week 12 | -146.2 ± 35 | -87.5 ± 51 |
| Week 36 | -272.0 ± 33 | -101.0 ± 47 |
The ELF Test is a non-invasive blood test that provides a simple, unitless numeric score that is used as a marker of collagen formation and fibrogenic activity and can be used to assess the risk of progression to cirrhosis. Scores below 9.8 indicate low risk of disease progression, and scores above 11.29 indicate high risk. The ELF score is derived from values of three serum biomarkers: hyaluronic acid (HA), procollagen III N-terminal peptide (PIIINP), and tissue inhibitor of metalloproteinase-1 (TIMP-1). The formula is 2.278 + 0.851 × ln(HA) + 0.751 × ln(PIIINP) + 0.394 × ln(TIMP-1); there are no minimum or maximum values.
| score on a scale | MGL-3196 | Placebo |
|---|---|---|
| Week 12 | -0.38 ± 0.09 | -0.02 ± 0.12 |
| Week 36 | -0.66 ± 0.12 | -0.18 ± 0.16 |
The Fib-4 score is a scoring system used to estimate the amount of scarring in the liver. It is based on common clinical parameters (age, AST, ALT, and platelets) and has been shown to have the best diagnostic accuracy for advanced fibrosis when compared with other noninvasive clinical scores. Scores are categorized into low (\<1.30), indeterminate (1.30-2.67), or high (\>2.67) risk of fibrosis. The formula for Fib-4 is: (Age \[yr\] x AST \[U/L\]) / ((PLT \[109/L\]) x (ALT \[U/L\])½); there are no minimum or maximum values
| score on a scale | MGL-3196 | Placebo |
|---|---|---|
| Week 12 | -0.03 ± 0.386 | 0.05 ± 0.374 |
| Week 36 | 0.02 ± 0.356 | 0.07 ± 0.436 |
Thyrotropin (TSH) was assessed at each study visit.
| mIU/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Thyrotropin at Week 12 | 0.096 ± 0.9136 | -0.101 ± 0.9742 |
Total thyroxine (FT4) was assessed at each study visit.
| μg/dL | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Total Thyroxine at Week 12 | -1.18 ± 0.958 | -0.07 ± 0.726 |
Free thyroxine (FT4) was assessed at each study visit.
| ng/dL | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Free Thyroxine at Week 12 | -0.147 ± 0.1154 | 0.001 ± 0.0930 |
Total Triiodothyronine (T3) was assessed at each study visit.
| μg/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Total Triiodothyronine at Week 12 | 0.03 ± 0.189 | 0.02 ± 0.236 |
Free triiodothyronine (T3) was assessed at each study visit.
| ng/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Free Triiodothyronine at Week 12 | 0.05 ± 0.363 | -0.02 ± 0.513 |
Thyroxine Binding Globulin was assessed at each study visit.
| mg/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Thyroxine Binding Globulin at Week 12 | -1.42 ± 3.859 | 0.39 ± 3.522 |
Reverse Triiodothyronine (T3) was assessed at each study visit.
| ng/dL | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Reverse Triiodothyronine Globulin at Week 12 | -5.22 ± 5.255 | -0.96 ± 5.757 |
Tyrotropin (TSH) was assessed at each study visit.
| mIU/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Thyrotropin at Week 36 | 0.034 ± 0.9705 | 0.043 ± 0.9481 |
Total thyroxine (FT4), thyrotropin (TSH) was assessed at each study visit.
| μg/dL | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Total Thyroxine at Week 36 | -1.10 ± 1.013 | -0.17 ± 0.846 |
Total free thyroxine (FT4) was assessed at each study visit.
| ng/dL | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Free Thyroxine Week 36 | -0.138 ± 0.1280 | -0.007 ± 0.1162 |
Total triiodothyronine (T3) was assessed at each study visit.
| μg/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Total Triiodothyronine at Week 36 | 0.02 ± 0.212 | -0.2 ± 0.190 |
Free triiodothyronine (T3) was assessed at each study visit.
| ng/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Free Triiodothyronine at Week 36 | 0.02 ± 0.404 | -0.02 ± 0.475 |
Thyroxine-binding globulin (TBG) was assessed at each study visit.
| mg/L | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Thyroxine-Binding Globulin at Week 36 | -0.38 ± 4.411 | 1.35 ± 5.639 |
Reverse triiodothyronine (T3) was assessed at each study visit.
| ng/dL | MGL-3196 | Placebo |
|---|---|---|
| Change From Baseline of Reverse Triiodothyronine at Week 36 | -4.41 ± 5.582 | -1.04 ± 5.493 |
Collected over Screening up to Week 36. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MGL-3196 Main Study | 0/84 (0%) | 5/84 (6%) | 73/84 (86.9%) |
| Placebo Main Study | 0/41 (0%) | 2/41 (4.9%) | 28/41 (68.3%) |
| Extension Study | 0/31 (0%) | 0/31 (0%) | 6/31 (19.4%) |
| Event | MGL-3196 Main Study | Placebo Main Study | Extension Study |
|---|---|---|---|
| Umbilical herniaGastrointestinal disorders | 0/84 | 1/41 | 0/31 |
| Bile duct stonesHepatobiliary disorders | 0/84 | 1/41 | 0/31 |
| Clostridium difficile colitisInfections and infestations | 1/84 | 0/41 | 0/31 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/84 | 0/41 | 0/31 |
| Spinal column stenosisMusculoskeletal and connective tissue disorders | 1/84 | 0/41 | 0/31 |
| Cerebrovascular accidentNervous system disorders | 1/84 | 0/41 | 0/31 |
| UreterolithiasisRenal and urinary disorders | 1/84 | 0/41 | 0/31 |
| Event | MGL-3196 Main Study | Placebo Main Study | Extension Study |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 31/84 | 4/41 | 2/31 |
| NauseaGastrointestinal disorders | 17/84 | 2/41 | 0/31 |
| HeadacheNervous system disorders | 11/84 | 6/41 | 0/31 |
| Urinary tract infectionInfections and infestations | 9/84 | 4/41 | 0/31 |
| DizzinessNervous system disorders | 6/84 | 4/41 | 0/31 |
| FatigueGeneral disorders | 4/84 | 4/41 | 0/31 |
| NasopharyngitisInfections and infestations | 5/84 | 2/41 | 3/31 |
| Abdominal Pain UpperGastrointestinal disorders | 7/84 | 1/41 | 0/31 |
| Abdominal PainGastrointestinal disorders | 6/84 | 3/41 | 0/31 |
| Accidental overdoseInjury, poisoning and procedural complications | 2/84 | 3/41 | 0/31 |
| Age, Continuous(years) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Mean | 51.8 ± 10.35 | 47.3 ± 11.71 | 50.3 ± 10.97 |
| Sex: Female, Male(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Female | 46 | 17 | 63 |
| Male | 38 | 24 | 62 |
| Ethnicity (NIH/OMB)(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 37 | 22 | 59 |
| Not Hispanic or Latino | 47 | 19 | 66 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 2 | 3 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| White | 80 | 37 | 117 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 0 | 1 |
| Hepatic Fat Fraction by MRI-PDFF at Screening(percentage) | MGL-3196 | Placebo | Total |
|---|---|---|---|
| Mean | 20.25 ± 6.843 | 19.63 ± 8.159 | 20.05 ± 7.274 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2016 to primary completion in Oct 2017, 12 months.
Results were first posted in Dec 2025, 8 years 1 month after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 12 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Resmetirom
Non-alcoholic Fatty Liver Disease →
Madrigal Pharmaceuticals, Inc. →